8-K: Seer Reports Strong Q2 2025 Growth, Launches New Proteomics Tools

Seer, Inc. announced second quarter 2025 financial results, reporting 32% revenue growth and the launch of new high-throughput Proteograph ONE assay and SP200 automation instrument.

Summary

• Revenue for the second quarter of 2025 was $4.1 million, a 32% increase from $3.1 million in the corresponding prior year period.
• Product revenue for Q2 2025 was $2.7 million, and service revenue was $1.2 million, which included $409 thousand of related party revenue.
• Gross profit reached $2.1 million with a gross margin of 52% for the second quarter of 2025.
• Operating expenses decreased by 21% to $22.6 million for Q2 2025, primarily due to a reduction in stock-based compensation from $7.3 million in the prior year to $3.7 million.
• Net loss improved to $19.4 million for the second quarter of 2025, compared to $22.9 million for the corresponding prior year period.
• Ended the quarter with approximately $263.3 million in cash, cash equivalents, and investments as of June 30, 2025.
• Reiterated full year 2025 revenue guidance in the range of $17 million to $18 million, representing 24% growth at the midpoint over full year 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to strong revenue growth, significant new product launches, a key collaboration, and improved net loss. However, the company remains unprofitable, and management noted ongoing macroeconomic pressures, which temper the overall positive outlook.

Positives

• Achieved strong revenue growth of 32% year-over-year for Q2 2025, reaching $4.1 million.
• Successfully launched new high-throughput Proteograph ONE assay and SP200 automation instrument, significantly enhancing platform scalability and efficiency.
• Announced a collaboration with Korea University to launch a 20,000-sample population-scale proteomics study utilizing the Proteograph ONE assay.
• Operating expenses decreased by 21% to $22.6 million, primarily driven by a reduction in stock-based compensation.
• Net loss improved to $19.4 million in Q2 2025, compared to $22.9 million in the prior year period.
• Maintained a robust cash position with approximately $263.3 million in cash, cash equivalents, and investments.

Negatives

• The company continues to report a net loss of $19.4 million for the quarter.
• Management noted continued macroeconomic pressures affecting the customer base.

Risks

• Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to be materially different from those expressed or implied.
• Continued macroeconomic pressures are affecting the customer base.

Future Outlook

Seer continues to expect full year 2025 revenue to be in the range of $17 million to $18 million, representing growth of 24% at the midpoint over full year 2024. The company anticipates its new high-throughput Proteograph ONE assay and SP200 automation instrument will enhance scalability and efficiency, supporting future growth and enabling population-scale studies.

Management Comments

• "Our team delivered a solid second quarter and achieved a pivotal milestone with the launches of our high-throughput Proteograph ONE assay and SP200 instrument, which significantly enhance the scalability and efficiency of our platform." Omid Farokhzad, Chair and CEO.
• "Seer was founded on the belief that we could transform the field of deep, unbiased proteomics. It's incredibly rewarding to see that vision come to fruition, with our technology now powering multiple population-scale studies." Omid Farokhzad, Chair and CEO.
• "I'm deeply proud of our team's relentless focus on innovation and execution, even with continued macroeconomic pressures affecting our customer base." Omid Farokhzad, Chair and CEO.

Industry Context

The announcement highlights Seer's continued innovation in the proteomics field, a rapidly evolving segment of life sciences focused on large-scale protein studies. The launch of high-throughput instruments and assays, coupled with a collaboration for a population-scale study utilizing AI-driven diagnostics for cancer, positions Seer at the forefront of addressing challenges like inconsistent data and limited throughput that have historically plagued traditional proteomic technologies. This aligns with broader industry trends towards automation, increased data scale, and the integration of AI in biological research and diagnostics.

Related Party Transactions

• Service revenue for the second quarter of 2025 included $409 thousand of related party revenue.
• Cost of revenue for the second quarter of 2025 included $69 thousand related to related party transactions.

Stakeholder Impact

• Shareholders: Positive impact from revenue growth, improved net loss, and new product launches, but continued net loss and macroeconomic pressures remain concerns. Reiteration of guidance provides stability.
• Customers: Benefit from enhanced scalability and efficiency through the new high-throughput Proteograph ONE assay and SP200 automation instrument.
• Employees: Recognition of the team's "relentless focus on innovation and execution" by the CEO.
• Partners (e.g., Korea University): Strengthened collaboration through the utilization of Seer's technology for population-scale studies.

Next Steps

• Host a conference call on August 6, 2025, at 1:30 pm Pacific Time / 4:30 pm Eastern Time to discuss the second quarter 2025 financial results.
• Continue to execute on the full year 2025 revenue guidance.
• Further development and adoption of the Proteograph Product Suite in the market.

Key Dates

Recommendation

Seer demonstrated solid Q2 2025 performance with 32% revenue growth and a reduced net loss, alongside the strategic launch of new high-throughput products and a significant collaboration. The reiteration of full-year guidance suggests performance is on track. While these are positive indicators of operational progress and market penetration in the proteomics space, the company remains unprofitable, and macroeconomic headwinds persist. The strong cash position provides runway. For a seasoned investor, the current filing suggests continued execution on strategy rather than a significant new catalyst for a 'strong buy' or 'sell' action, warranting a 'hold' position to observe further progress towards profitability and sustained market adoption.

Keywords

Proteomics, Life Sciences, Biotechnology, Proteograph, SP200, AI Diagnostics, Cancer Research, Automation, SEC Filing, Financial Results